Sanofi Revenue Growth Rates (SNY), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Sanofi  (NASDAQ: SNY)
 

SNY's Revenue Growth by Quarter and Year

Sanofi's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

SNY Revenue (in millions $) FY 2025 FY 2024 FY 2023 FY 2022
4th Quarter December 52,321.04
3rd Quarter September 0.00
2nd Quarter June 0.00
1st Quarter March 0.00
FY 52,321.04

SNYs Annual Revenue
Sanofi's Revenue in the fiscal year 2025 $ 52,321.04 millions
Sanofi's Revenue in the fiscal year 2024 $ 49,599.72 millions
Sanofi's Revenue in the fiscal year 2023 $ 52,016.96 millions
Sanofi's Revenue in the fiscal year 2022 $ 50,835.68 millions
Sanofi's Revenue in the fiscal year 2021 $ 44,718.83 millions




SNY Revenue fourth quarter 2025 Y/Y Growth Comment
Sanofi showed record Revenue improvement in the fourth quarter 2025 with 5.49% from the fourth quarter 2025 2024, to $ 52,321.04 millions.

Looking into fourth quarter 2025 results within Major Pharmaceutical Preparations industry 128 other companies have achieved higher Revenue growth. While Sanofi' s Revenue increase of 5.49% ranks overall at the positon no. 2381 in the fourth quarter 2025.


SNY Revenue ( Y/Y Growth %) 2025
 2024 2023 2022
4th Quarter December 5.49 % -4.65 % 2.32 % 21.46 %
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY   5.49 % -4.65 % 2.32 % -

Financial Statements
Sanofi's fourth quarter 2025 Revenue $ 52,321.04 millions SNY's Income Statement
Sanofi's fourth quarter 2024 Revenue $ 49,599.72 millions Quarterly SNY's Income Statement


SNY Revenue (Quarter on Quarter Growth %)

 2025
 2024 2023 2022
4th Quarter December - - - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY (Year on Year)   5.49 % -4.65 % 2.32 % -


Back to SNY Growth rate Comparisons >> Back to SNY Growth rate Comparisons >>


Revenue fourth quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #129
Healthcare Sector #359
Overall #2381

Revenue Y/Y Growth Statistics
High Average Low
5.49 % 1.59 % -4.65 %
(Dec 31 2022)   (Dec 31 2024)
Revenue fourth quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #129
Healthcare Sector #359
Overall #2381
Revenue Y/Y Growth Statistics
High Average Low
5.49 % 1.59 % -4.65 %
(Dec 31 2022)   (Dec 31 2024)

Revenue by Quarter for the Fiscal Years 2022, 2023, 2024, 2025

Sanofi's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


SNY's IV. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


SNY's IV. Quarter Q/Q Revenue Comment


Sanofi's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Dec 31 2024)		 12 Months Ending
(Dec 31 2023)		 12 Months Ending
(Dec 31 2022)		 12 Months Ending
(Dec 31 2021)
Cumulative Revenue 12 Months Ending $ 52,321.04 $ 49,599.72 $ 52,016.96 $ 50,835.68 $ 44,718.83
Y / Y Revenue Growth (TTM) 5.49 % -4.65 % 2.32 % 13.68 % 6.85 %
Year on Year Revenue Growth Overall Ranking # 316 # 610 # 0 # 0 # 0
Seqeuential Revenue Change (TTM) 5.49 % -4.65 % 2.32 % 13.68 % 6.85 %
Seq. Revenue Growth (TTM) Overall Ranking # 316 # 613 # 0 # 0 # 0


Cumulative Revenue growth Comment
Sanofi saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 5.49% year on year, to $ 52,321 millions if the fiscal year would have ended in Dec 31 2025.
Sanofi's trailing twelve months Revenue growth was higher than company's average 4.78% and higher than -4.65% growth in Dec 31 2024.

In the Healthcare sector 59 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 316, from total ranking in previous quarter at 610.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 30
Healthcare Sector # 60
Overall # 316

Revenue TTM Y/Y Growth Statistics
High Average Low
21.46 %
 4.78 %
-4.65 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 30
Sector # 60
S&P 500 # 316
Cumulative Revenue growth Comment
Sanofi saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 5.49% year on year, to $ 52,321 millions if the fiscal year would have ended in Dec 31 2025.
Sanofi's trailing twelve months Revenue growth was higher than company's average 4.78% and higher than -4.65% growth in Dec 31 2024.
The momentum is even more impressive from twelve months ended Dec 31 2024 exhibited at 5.49 % increase from $49599.72 millions in the period from Dec 31 2024 to Dec 31 2021.

In the Healthcare sector 59 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 316, from total ranking in previous quarter at 610.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 30
Healthcare Sector # 60
Overall # 316

Revenue TTM Y/Y Growth Statistics
High Average Low
21.46 %
4.78 %
-4.65 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 30
Sector # 60
S&P 500 # 316




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
SNY's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue increase for the quarter ending Dec 31 2025 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2025
Novartis Ag9.57%$ 9.574 millions
Vertex Pharmaceuticals Inc9.55%$ 9.547 millions
Procept Biorobotics Corporation9.53%$ 9.532 millions
Acadia Pharmaceuticals Inc 9.39%$ 9.394 millions
Bausch Health Companies Inc 9.26%$ 9.261 millions
Cuprina Holdings cayman Limited9.20%$ 9.197 millions
Burning Rock Biotech Limited9.18%$ 9.184 millions
Steris Plc9.17%$ 9.166 millions
Johnson and Johnson9.08%$ 9.076 millions
Universal Health Services Inc 9.05%$ 9.051 millions
Upstream Bio Inc 8.97%$ 8.972 millions
Tenet Healthcare Corp8.97%$ 8.971 millions
Fresenius Medical Care Ag8.77%$ 8.771 millions
Option Care Health Inc 8.63%$ 8.631 millions
Astrazeneca Plc8.63%$ 8.629 millions
Amgen Inc 8.58%$ 8.585 millions
Integer Holdings Corporation8.38%$ 8.377 millions
Vivosim Labs Inc 8.33%$ 8.333 millions
China Pharma Holdings Inc8.11%$ 8.113 millions
Novocure Limited8.11%$ 8.113 millions
Mettler toledo International Inc 8.10%$ 8.095 millions
Yunhong Green Cti Ltd 8.03%$ 8.028 millions
Baxter International Inc 8.03%$ 8.028 millions
Nuwellis Inc 8.02%$ 8.021 millions
Conmed Corporation7.88%$ 7.878 millions
Ardelyx inc 7.82%$ 7.824 millions
Henry Schein Inc 7.71%$ 7.709 millions
West Pharmaceutical Services Inc 7.65%$ 7.654 millions
Catalyst Pharmaceuticals Inc 7.61%$ 7.610 millions
Vanda Pharmaceuticals Inc 7.58%$ 7.579 millions


About Sanofi Revenue Growth Rates (SNY), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Sanofi (CIK 1121404).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001628280-26-008403
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Sanofi’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.